The innate immune system is composed of a cellular arm and a humoral arm. Components of the humoral arm include members of the complement cascade and soluble pattern recognition molecules (PRMs). These PRMs recognize pathogen-associated molecular patterns and are functional ancestors of antibodies, playing a role in complement activation, opsonization and agglutination. Pentraxins consist of a set of multimeric soluble proteins and represent the prototypic components of humoral innate immunity. The prototypic long pentraxin PTX3 is highly conserved in evolution and produced by somatic and innate immune cells after proinflammatory stimuli. PTX3 interacts with a set of self, nonself and modified self ligands and exerts essential roles in innate immunity, inflammation control and matrix deposition. In addition, translational studies suggest that PTX3 may be a useful biomarker of human pathologies complementary to C-reactive protein. In this study, we will review the general functions of pentraxins in innate immunity and inflammation, focusing our attention on the prototypic long pentraxin PTX3.

Keywords:
Clinical biomarkers, Inflammation, Innate immunity, Pattern recognition molecules, Pentraxin
1.
Abernethy TJ, Avery OT: The occurrence during acute infections of a protein not normally present in the blood. I. Distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus. J Exp Med 1941;73:173-182.
2.
Tillett WS, Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571.
3.
Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-366.
4.
Inforzato A, Doni A, Barajon I, Leone R, Garlanda C, Bottazzi B, Mantovani A: PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol 2013;25:79-85.
5.
Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
6.
Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB: C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008;264:295-314.
7.
Bijl M, Bootsma H, Van Der Geld Y, Limburg PC, Kallenberg CG, Van Rijswijk MH: Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004;63:831-835.
8.
Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW: The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J Exp Med 1999;190:585-590.
9.
Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD: Structural recognition and functional activation of FcγR by innate pentraxins. Nature 2008;456:989-992.
10.
Roumenina LT, Ruseva MM, Zlatarova A, Ghai R, Kolev M, Olova N, Gadjeva M, Agrawal A, Bottazzi B, Mantovani A, Reid KB, Kishore U, Kojouharova MS: Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006;45:4093-4104.
11.
Ng PM, Le Saux A, Lee CM, Tan NS, Lu J, Thiel S, Ho B, Ding JL: C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J 2007;26:3431-3440.
12.
Tanio M, Wakamatsu K, Kohno T: Binding site of C-reactive protein on M-ficolin. Mol Immunol 2009;47:215-221.
13.
Sjöberg AP, Trouw LA, McGrath FD, Hack CE, Blom AM: Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol 2006;176:7612-7620.
14.
Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S: Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999;163:3957-3962.
15.
Mihlan M, Stippa S, Jozsi M, Zipfel PF: Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009;16:1630-1640.
16.
Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ: Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010;285:1053-1065.
17.
Nauta AJ, Daha MR, van Kooten C, Roos A: Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003;24:148-154.
18.
Gershov D, Kim S, Brot N, Elkon KB: C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-1364.
19.
Garcia de Frutos P, Hardig Y, Dahlback B: Serum amyloid P component binding to C4b-binding protein. J Biol Chem 1995;270:26950-26955.
20.
Szalai AJ: The antimicrobial activity of C-reactive protein. Microbes Infect 2002;4:201-205.
21.
Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH Jr: Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000;68:5652-5656.
22.
Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB: Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci USA 2000;97:14584-14589.
23.
Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, Della Valle G, Dejana E, Mantovani A, Introna M: Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-22197.
24.
Lee GW, Lee TH, Vilcek J: TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993;150:1804-1812.
25.
Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M: Characterization of the promoter for the human long pentraxin PTX3. Role of NF-κB in tumor necrosis factor-α and interleukin-1β regulation. J Biol Chem 1997;272:8172-8178.
26.
Altmeyer A, Klampfer L, Goodman AR, Vilcek J: Promoter structure and transcriptional activation of the murine TSG-14 gene encoding a tumor necrosis factor/interleukin-1-inducible pentraxin protein. J Biol Chem 1995;270:25584-25590.
27.
Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL: Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:925-931.
28.
Han B, Mura M, Andrade CF, Okutani D, Lodyga M, dos Santos CC, Keshavjee S, Matthay M, Liu M: TNFα-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol 2005;175:8303-8311.
29.
Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D'Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A: Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817-32823.
30.
Inforzato A, Peri G, Doni A, Garlanda C, Mantovani A, Bastone A, Carpentieri A, Amoresano A, Pucci P, Roos A, Daha MR, Vincenti S, Gallo G, Carminati P, De Santis R, Salvatori G: Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry 2006;45:11540-11551.
31.
Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, Verdoliva A, Vincenti S, Gallo G, Chiapparino C, Pacello L, Nucera E, Serlupi-Crescenzi O, Day AJ, Bottazzi B, Mantovani A, De Santis R, Salvatori G: Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem 2008;283:10147-10161.
32.
Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, Rivieccio V, Briggs DC, Kadler KE, Verdoliva A, Bottazzi B, Mantovani A, Salvatori G, Day AJ: The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem 2010;285:17681-17692.
33.
Shrive AK, Metcalfe AM, Cartwright JR, Greenhough TJ: C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of limulus SAP. J Mol Biol 1999;290:997-1008.
34.
Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, Romani L, Garlanda C, Mantovani A: Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003;33:2886-2893.
35.
Nauta AJ, de Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten J, Rastaldi MP, Daha MR, van Kooten C, Roos A: Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 2005;67:543-553.
36.
Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, Moustaid-Moussa N, Pasqualini F, Mantovani A, Ailhaud G, Amri EZ: Characterization of the long pentraxin PTX3 as a TNFα-induced secreted protein of adipose cells. J Lipid Res 2003;44:994-1000.
37.
Goodman AR, Levy DE, Reis LF, Vilcek J: Differential regulation of TSG-14 expression in murine fibroblasts and peritoneal macrophages. J Leukoc Biol 2000;67:387-395.
38.
Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, Peri G, Breviario F, Salmona M, De Gregorio L, Dragani TA, Srinivasan N, Blundell TL, Hamilton TA, Mantovani A: Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996;87:1862-1872.
39.
dos Santos CC, Han B, Andrade CF, Bai X, Uhlig S, Hubmayr R, Tsang M, Lodyga M, Keshavjee S, Slutsky AS, Liu M: DNA microarray analysis of gene expression in alveolar epithelial cells in response to TNFα, LPS, and cyclic stretch. Physiol Genomics 2004;19:331-342.
40.
Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, Mantovani A: The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009;227:9-18.
41.
Polentarutti N, Picardi G, Basile A, Cenzuales S, Rivolta A, Matteucci C, Peri G, Mantovani A, Introna M: Interferon-gamma inhibits expression of the long pentraxin PTX3 in human monocytes. Eur J Immunol 1998;28:496-501.
42.
Doni A, Michela M, Bottazzi B, Peri G, Valentino S, Polentarutti N, Garlanda C, Mantovani A: Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol 2006;79:797-802.
43.
Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Puthia M, Riva F, Barbati E, Nebuloni M, Cvetko Krajinovic L, Markotic A, Valentino S, Doni A, Tartari S, Graziani G, Montanelli A, Delneste Y, Svanborg C, Garlanda C, Mantovani A: The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 2014;40:621-632.
44.
Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda C, Mantovani A: Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055-1064.
45.
Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL: Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009;120:699-708.
46.
Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, Garlanda C, Romani L, Gascan H, Bellocchio S, Bozza S, Cassatella MA, Jeannin P, Mantovani A: The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007;204:793-804.
47.
Jaillon S, Mancuso G, Hamon Y, Beauvillain C, Cotici V, Midiri A, Bottazzi B, Nebuloni M, Garlanda C, Fremaux I, Gauchat JF, Descamps P, Beninati C, Mantovani A, Jeannin P, Delneste Y: Prototypic long pentraxin PTX3 is present in breast milk, spreads in tissues, and protects neonate mice from Pseudomonas aeruginosa lung infection. J Immunol 2013;191:1873-1882.
48.
Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma O, Hack EC, Daha MR, Roos A: Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003;33:465-473.
49.
Deban L, Jarva H, Lehtinen MJ, Bottazzi B, Bastone A, Doni A, Jokiranta TS, Mantovani A, Meri S: Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol 2008;181:8433-8440.
50.
Kopp A, Strobel S, Tortajada A, Rodriguez de Cordoba S, Sanchez-Corral P, Prohaszka Z, Lopez-Trascasa M, Jozsi M: Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor H-related protein 1 to pentraxin 3. J Immunol 2012;189:1858-1867.
51.
Braunschweig A, Jozsi M: Human pentraxin 3 binds to the complement regulator C4b-binding protein. PLoS One 2011;6:e23991.
52.
Gout E, Moriscot C, Doni A, Dumestre-Perard C, Lacroix M, Perard J, Schoehn G, Mantovani A, Arlaud GJ, Thielens NM: M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J Immunol 2011;186:5815-5822.
53.
Ma YJ, Doni A, Hummelshoj T, Honore C, Bastone A, Mantovani A, Thielens NM, Garred P: Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem 2009;284:28263-28275.
54.
Ma YJ, Doni A, Skjoedt MO, Honore C, Arendrup M, Mantovani A, Garred P: Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem 2011;286:3405-3417.
55.
Ma YJ, Doni A, Romani L, Jurgensen HJ, Behrendt N, Mantovani A, Garred P: Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol 2013;191:1324-1333.
56.
Diniz SN, Nomizo R, Cisalpino PS, Teixeira MM, Brown GD, Mantovani A, Gordon S, Reis LF, Dias AA: PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol 2004;75:649-656.
57.
Moalli F, Paroni M, Veliz Rodriguez T, Riva F, Polentarutti N, Bottazzi B, Valentino S, Mantero S, Nebuloni M, Mantovani A, Bragonzi A, Garlanda C: The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol 2011;186:5425-5434.
58.
Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B, Peri G, Doni A, Vago L, Botto M, De Santis R, Carminati P, Siracusa G, Altruda F, Vecchi A, Romani L, Mantovani A: Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-186.
59.
Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, Maina V, Magistrelli G, Haeuw JF, Hoeffel G, Thieblemont N, Corvaia N, Garlanda C, Delneste Y, Mantovani A: Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 2005;22:551-560.
60.
Bozza S, Bistoni F, Gaziano R, Pitzurra L, Zelante T, Bonifazi P, Perruccio K, Bellocchio S, Neri M, Iorio AM, Salvatori G, De Santis R, Calvitti M, Doni A, Garlanda C, Mantovani A, Romani L: Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 2006;108:3387-3396.
61.
Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE, Bottazzi B, Romani L, Mantovani A: Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 2008;180:3391-3398.
62.
Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L, Salvatori G, De Santis R, Carminati P, Mantovani A, Romani L: Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004;48:4414-4421.
63.
D'Angelo C, De Luca A, Zelante T, Bonifazi P, Moretti S, Giovannini G, Iannitti RG, Zagarella S, Bozza S, Campo S, Salvatori G, Romani L: Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 2009;183:4609-4618.
64.
Moalli F, Doni A, Deban L, Zelante T, Zagarella S, Bottazzi B, Romani L, Mantovani A, Garlanda C: Role of complement and Fcγ receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood 2010;116:5170-5180.
65.
Moalli F, Jaillon S, Inforzato A, Sironi M, Bottazzi B, Mantovani A, Garlanda C: Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol 2011;2011:830421.
66.
Cotena A, Maina V, Sironi M, Bottazzi B, Jeannin P, Vecchi A, Corvaia N, Daha MR, Mantovani A, Garlanda C: Complement dependent amplification of the innate response to a cognate microbial ligand by the long pentraxin PTX3. J Immunol 2007;179:6311-6317.
67.
Soares AC, Souza DG, Pinho V, Vieira AT, Nicoli JR, Cunha FQ, Mantovani A, Reis LF, Dias AA, Teixeira MM: Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes Infect 2006;8:1321-1329.
68.
Job ER, Deng YM, Tate MD, Bottazzi B, Crouch EC, Dean MM, Mantovani A, Brooks AG, Reading PC: Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J Immunol 2010;185:4284-4291.
69.
Job ER, Bottazzi B, Short KR, Deng YM, Mantovani A, Brooks AG, Reading PC: A single amino acid substitution in the hemagglutinin of H3N2 subtype influenza A viruses is associated with resistance to the long pentraxin PTX3 and enhanced virulence in mice. J Immunol 2014;192:271-281.
70.
Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, Assael BM, Badolato R: PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 2010;11:665-670.
71.
Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, Rabna P, Worwui A, Chapman H, Diatta M, Adegbola RA, Hill PC, Ostergaard L, Williams SM, Sirugo G: DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun 2007;8:456-467.
72.
Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, Loffler J, Maertens JA, Bell AS, Inforzato A, Barbati E, Almeida B, Santos e Sousa P, Barbui A, Potenza L, Caira M, Rodrigues F, Salvatori G, Pagano L, Luppi M, Mantovani A, Velardi A, Romani L, Carvalho A: Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014;370:421-432.
73.
Barbati E, Specchia C, Villella M, Rossi ML, Barlera S, Bottazzi B, Crociati L, d'Arienzo C, Fanelli R, Garlanda C, Gori F, Mango R, Mantovani A, Merla G, Nicolis EB, Pietri S, Presbitero P, Sudo Y, Villella A, Franzosi MG: Influence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels. PLoS One 2012;7:e53030.
74.
Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A: Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 2011;343:237-249.
75.
Lech M, Rommele C, Grobmayr R, Eka Susanti H, Kulkarni OP, Wang S, Grone HJ, Uhl B, Reichel C, Krombach F, Garlanda C, Mantovani A, Anders HJ: Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int 2013;83:647-661.
76.
Han B, Haitsma JJ, Zhang Y, Bai X, Rubacha M, Keshavjee S, Zhang H, Liu M: Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intensive Care Med 2011;37:334-342.
77.
Xiao Y, Yang N, Zhang Q, Wang Y, Yang S, Liu Z: Pentraxin 3 inhibits acute renal injury-induced interstitial fibrosis through suppression of IL-6/Stat3 pathway. Inflammation 2014;37:1895-1901.
78.
Mantovani A, Valentino S, Gentile S, Inforzato A, Bottazzi B, Garlanda C: The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann NY Acad Sci 2013;1285:1-14.
79.
Souza DG, Amaral FA, Fagundes CT, Coelho FM, Arantes RM, Sousa LP, Matzuk MM, Garlanda C, Mantovani A, Dias AA, Teixeira MM: The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009;174:1309-1318.
80.
Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, Inforzato A, Vincenti S, Bracci L, Mastroianni D, Presta M: Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006;281:22605-22613.
81.
Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, Amadori A, Mantovani A, Presta M: Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-99.
82.
Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A: Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol 2013;229:87-98.
83.
Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, Mantovani A, Giacca M, Presta M: Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005;25:1837-1842.
84.
Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M: Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther 2011;10:1600-1610.
85.
Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M: Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol 2013;230:228-238.
86.
Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M: Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther 2013;12:2760-2771.
87.
Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, Doni A, Bastone A, Mantovani G, Beck Peccoz P, Salvatori G, Mahoney DJ, Day AJ, Siracusa G, Romani L, Mantovani A: PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004;131:1577-1586.
88.
Scarchilli L, Camaioni A, Bottazzi B, Negri V, Doni A, Deban L, Bastone A, Salvatori G, Mantovani A, Siracusa G, Salustri A: PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem 2007;282:30161-30170.
89.
Zhang S, Zhu YT, Chen SY, He H, Tseng SC: Constitutive expression of pentraxin 3 (PTX3) protein by human amniotic membrane cells leads to formation of the heavy chain (HC)-hyaluronan (HA)-PTX3 complex. J Biol Chem 2014;289:13531-13542.
90.
Jeannin P, Jaillon S, Delneste Y: Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008;20:530-537.
91.
van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A, Kallenberg CG: The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 2004;50:2667-2674.
92.
Rovere P, Peri G, Fazzini F, Bottazzi B, Doni A, Bondanza A, Zimmermann VS, Garlanda C, Fascio U, Sabbadini MG, Rugarli C, Mantovani A, Manfredi AA: The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300-4306.
93.
Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, Rovere-Querini P: The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 2006;80:87-95.
94.
Trouw LA, Bengtsson AA, Gelderman KA, Dahlback B, Sturfelt G, Blom AM: C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007;282:28540-28548.
95.
Jaillon S, Jeannin P, Hamon Y, Fremaux I, Doni A, Bottazzi B, Blanchard S, Subra JF, Chevailler A, Mantovani A, Delneste Y: Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ 2009;16:465-474.
96.
Guo T, Ke L, Qi B, Wan J, Ge J, Bai L, Cheng B: PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages. J Clin Immunol 2012;32:330-339.
97.
Lech M, Rommele C, Kulkarni OP, Susanti HE, Migliorini A, Garlanda C, Mantovani A, Anders HJ: Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One 2011;6:e20118.
98.
Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, Cugno M, Iapichino G, Gattinoni L, Pesenti A, Mantovani A: Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 2010;36:621-629.
99.
Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG, Manfredi AA, Mantovani A, Querini PR: PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-2850.
100.
Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A: Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-2308.
101.
Biagi E, Col M, Migliavacca M, Dell'Oro M, Silvestri D, Montanelli A, Peri G, Mantovani A, Biondi A, Rossi MR: PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. J Pediatr Hematol Oncol 2008;30:881-885.
102.
Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, van Deuren M: Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 2009;31:28-32.
103.
Mairuhu AT, Peri G, Setiati TE, Hack CE, Koraka P, Soemantri A, Osterhaus AD, Brandjes DP, van der Meer JW, Mantovani A, van Gorp EC: Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 2005;76:547-552.
104.
Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, Benagiano M, D'Elios MM, Mantovani A, Del Prete G: IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005;7:1-8.
105.
Wagenaar JF, Goris MG, Gasem MH, Isbandrio B, Moalli F, Mantovani A, Boer KR, Hartskeerl RA, Garlanda C, van Gorp EC: Long pentraxin PTX3 is associated with mortality and disease severity in severe leptospirosis. J Infect 2009;58:425-432.
106.
Hamon Y, Jaillon S, Person C, Ginies JL, Garo E, Bottazzi B, Ghamrawi S, Urban T, Subra JF, Bouchara JP, Mantovani A, Jeannin P, Delneste Y: Proteolytic cleavage of the long pentraxin PTX3 in the airways of cystic fibrosis patients. Innate Immun 2013;19:611-622.
107.
Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P: Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 2013;8:e73119.
108.
Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A: Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-1407.
109.
Uusitalo-Seppala R, Huttunen R, Aittoniemi J, Koskinen P, Leino A, Vahlberg T, Rintala EM: Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One 2013;8:e53661.
110.
Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, Valente M, Cattin L, Guarnieri G, Barazzoni R: Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009;9:243-248.
111.
Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R: PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-641.
112.
Jylhava J, Haarala A, Kahonen M, Lehtimaki T, Jula A, Moilanen L, Kesaniemi YA, Nieminen MS, Hurme M: Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011;164:211-217.
113.
Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-2354.
114.
Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM: Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arterioscler Thromb Vasc Biol 2009;29:594-599.
115.
Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vardal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials: Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012;14:992-999.
116.
Ferratini M, Ripamonti V, Masson S, Grati P, Racca V, Cuccovillo I, Raimondi E, Capomolla S, Macchi C, Coruzzi P, Vago T, Calvo M, Mantovani A, Latini R: Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients. J Cardiopulm Rehabil Prev 2012;32:17-24.
117.
Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T: Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-167.
118.
Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Naruse H, Tanaka I, Nomura M, Hishida H, Ozaki Y: Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010;210:220-225.
119.
Naito Y, Tsujino T, Akahori H, Ohyanagi M, Mitsuno M, Miyamoto Y, Hao H, Hirota S, Masuyama T: Increase in tissue and circulating pentraxin3 levels in patients with aortic valve stenosis. Am Heart J 2010;160:685-691.
120.
Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K: Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008;197:368-374.
121.
Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, Pardi G, Mantovani A: Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2006;194:1347-1353.
122.
Rovere-Querini P, Antonacci S, Dell'Antonio G, Angeli A, Almirante G, Cin ED, Valsecchi L, Lanzani C, Sabbadini MG, Doglioni C, Manfredi AA, Castiglioni MT: Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol 2006;108:148-155.
123.
Cozzi V, Garlanda C, Nebuloni M, Maina V, Martinelli A, Calabrese S, Cetin I: PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta 2012;33:1039-1044.
124.
Assi F, Fruscio R, Bonardi C, Ghidini A, Allavena P, Mantovani A, Locatelli A: Pentraxin 3 in plasma and vaginal fluid in women with preterm delivery. BJOG 2007;114:143-147.
125.
Cruciani L, Romero R, Vaisbuch E, Kusanovic JP, Chaiworapongsa T, Mazaki-Tovi S, Dong Z, Kim SK, Ogge G, Yeo L, Mittal P, Hassan SS: Pentraxin 3 in maternal circulation: an association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med 2010;23:1097-1105.
126.
Kacerovsky M, Tosner J, Drahosova M, Hornychova H, Andrys C: Pentraxin 3 in amniotic fluid as a marker of intra-amniotic inflammation in women with preterm premature rupture of membranes. Int J Gynaecol Obstet 2010;108:203-206.
127.
Martin LF, Moco NP, Ramos BR, Camargo RP, Silva MG: Pentraxin-3 concentration in the amniotic fluid of women at term, in spontaneous preterm labor and when not in labor. Eur J Obstet Gynecol Reprod Biol 2014;176:86-89.
128.
Cruciani L, Romero R, Vaisbuch E, Kusanovic JP, Chaiworapongsa T, Mazaki-Tovi S, Mittal P, Ogge G, Gotsch F, Erez O, Kim SK, Dong Z, Pacora P, Lamont RF, Yeo L, Hassan SS, Di Renzo GC: Pentraxin 3 in amniotic fluid: a novel association with intra-amniotic infection and inflammation. J Perinat Med 2010;38:161-171.
129.
Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, Fratini M, Fraticelli P, Sambo P, Di Loreto C, Doni A, Introna M, Gabrielli A: Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:196-202.
130.
Augusto JF, Onno C, Blanchard S, Dubuquoi S, Mantovani A, Chevailler A, Jeannin P, Subra JF: Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:442-444.
131.
Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, Shoenfeld Y, Doria A: IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010;69:1704-1710.
132.
Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP: Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009;8:2746-2758.
133.
Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators: Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011;96:315-318.
134.
Locatelli M, Ferrero S, Martinelli Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, Bello L, Valentino S, Barbati E, Nebuloni M, Mantovani A, Garlanda C: The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol 2013;260:99-106.
135.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group; Gertig D, DeFazio A, Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-5208.
136.
Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P: Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70:2235-2244.
137.
Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M, Mari E, Sentinelli S, Petrangeli E, Gallucci M, Di Silverio F, Russo MA: Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 2009;69:1245-1255.
138.
Wang JX, He YL, Zhu ST, Yang S, Zhang ST: Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol 2011;17:4225-4230.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.